Sangeetha Venugopal

Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19

Leonard Naymagon, Nicole Zubizarreta, Jonathan Feld et al. · Thrombosis Research · 2020 · 129 citations · Full text

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Sangeetha Venugopal, Koichi Takahashi, Naval Daver et al. · Blood Cancer Journal · 2022 · 91 citations · Full text

Outcomes in patients with newly diagnosed <i>TP53</i>‐mutated acute myeloid leukemia with or without venetoclax‐based therapy

Sangeetha Venugopal, Mahran Shoukier, Marina Konopleva et al. · Cancer · 2021 · 60 citations · Full text

Targeted therapy with the mutant <i>IDH2</i> inhibitor enasidenib for high-risk <i>IDH2</i>-mutant myelodysplastic syndrome

Courtney D. DiNardo, Sangeetha Venugopal, Curtis A. Lachowiez et al. · Blood Advances · 2022 · 60 citations · Full text

Clinical outcomes associated with <i>NPM1</i> mutations in patients with relapsed or refractory AML

Ghayas C. Issa, Aram Bidikian, Sangeetha Venugopal et al. · Blood Advances · 2022 · 50 citations · Full text

Mixed-phenotype Acute Leukemia, Pathology, Favorable Prognosis +17